FDA警告前后膳食补充剂中非尼布特(phenibut)含量的变化
该研究检测了FDA警告前后市售含非尼布特膳食补充剂的实际含量。纳入4个品牌的产品,用液相色谱-飞行时间质谱和同位素稀释法定量。警告前4个品牌中仅2个检出非尼布特(484 mg和487 mg/份);警告后全部4个品牌均检出,范围21–1164 mg/份,2个品牌为警告后首次检出,3个品牌含量增加。提示FDA警告未能减少补充剂中非尼布特暴露,急诊医生需警惕患者服用补充剂导致非尼布特中毒或戒断。
要点
- FDA警告后4个品牌全部检出非尼布特,含量21–1164 mg/份,3个品牌含量较警告前增加。
- 警告前仅2/4品牌检出,剂量484 mg和487 mg/份;2个品牌在警告后才首次检出。
- 最高检出量达1164 mg/份,为俄罗斯典型250 mg药片的450%以上。
- 非尼布特可致嗜睡、谵妄、精神病和昏迷,已有80余例昏迷和死亡与服用或戒断相关。
- FDA从未批准非尼布特作为处方药,且已警告其不允许用于非处方补充剂。
适用人群与场景
- 服用标有非尼布特或其同义词的膳食补充剂者,在急诊或ICU出现不明原因嗜睡、谵妄、精神病或昏迷时需考虑非尼布特中毒。
- 原文未提及特定纳入或排除人群的年龄、基础病等条件。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 服用含非尼布特补充剂后出现嗜睡、谵妄、精神病或昏迷,需警惕非尼布特中毒。
- 非尼布特戒断也可能相关,原文提及80余例昏迷和死亡与服用和戒断相关。
研究设计与关键结果
- 研究类型为实验分析,纳入4个品牌膳食补充剂,用液相色谱-飞行时间质谱和同位素稀释法定量。
- FDA警告前2/4品牌含非尼布特,剂量484 mg和487 mg/份。
- FDA警告后4/4品牌含非尼布特,剂量21–1164 mg/份。
- 2个品牌在FDA警告后首次检出非尼布特;3/4产品警告后非尼布特含量增加。
- 最高检出量达1164 mg/份,为俄罗斯典型250 mg药片的450%以上。
证据类型、等级与局限
- 证据类型为实验分析研究,样本为4个品牌补充剂,非临床人群研究。
- 局限:样本量小(仅4个品牌),仅检测特定品牌,不能代表所有市售产品;原文未提及证据等级。
对床旁实践的改变
- 急诊/ICU遇到服用膳食补充剂后出现嗜睡、谵妄、精神病或昏迷的患者,应询问非尼布特补充剂使用,不应因FDA警告而降低怀疑。
- 原文提示FDA警告后部分产品非尼布特含量反而增加,临床不能假设警告后产品更安全。
- 适用人群为服用含非尼布特补充剂者;原文未提及不适用人群。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Phenibut is used to treat anxiety, insomnia, alcohol withdrawal and other conditions in Russia. The drug, however, has abuse potential and may cause lethargy, delirium, psychosis and coma. In the United States (US), the US Food and Drug Administration (FDA) has never approved the use of phenibut as a prescription medication, but the drug is available over-the-counter in dietary supplements. More than 80 cases of coma and death have been associated with phenibut consumption and withdrawal, and the FDA recently warned that the drug is not permitted in over-the-counter supplements. We designed our study to determine the presence and quantity of phenibut in over-the-counter supplements before and after the FDA warnings.
METHODS: Phenibut products were included if they (a) listed phenibut or a synonym as an ingredient on the label, (b) were labeled as a dietary supplement, and (c) were available for sale both before and after the FDA warning. Supplements were analyzed by liquid chromatography time-of-flight mass spectrometry; quantification was performed by isotope dilution method.
RESULTS: Four brands of dietary supplements labeled as containing phenibut met the inclusion criteria. Prior to the FDA warnings, two of the four brands contained phenibut, at dosages of 484 mg and 487 mg per serving. After the FDA warning, all four products contained phenibut, ranging in dosages from 21 mg to 1,164 mg per serving. Phenibut was first detected only after the FDA warnings in two brands, and the quantity of phenibut increased in three of four products after the FDA warnings. Quantities detected per dose were as much as 450% greater than a typical 250 mg pharmaceutical tablet manufactured in Russia.
CONCLUSION: Following FDA issuing an advisory that phenibut is not permitted in dietary supplements, the quantity of phenibut increased in 3 of 4 brands of over-the-counter phenibut supplements.
参考来源
- Cohen PA, Ellison RR, Travis JC, et al. Quantity of phenibut in dietary supplements before and after FDA warnings. Clin Toxicol (Phila). 2021. PMID: 34550038. doi:10.1080/15563650.2021.1973020
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。